Understanding What GLP 1 Medications Actually Do

Glucagon like peptide 1 receptor agonists are medications originally developed for type 2 diabetes. They mimic a natural hormone that increases insulin secretion, slows gastric emptying, and promotes a feeling of fullness after eating.

Over the past several years, large clinical trials have demonstrated that these medications also produce substantial weight loss in people with obesity, even without diabetes. As demand increased globally, questions about long term safety and sustainability became more urgent.

What The STEP Trials Found About Weight Loss

The STEP clinical trial program, published in the New England Journal of Medicine, evaluated once weekly semaglutide in adults with overweight or obesity.

Participants receiving semaglutide achieved average weight reductions of approximately fifteen percent over sixty eight weeks. In comparison, placebo groups with lifestyle counseling alone achieved significantly smaller reductions.

This magnitude of weight loss is clinically meaningful. Research shows that even five to ten percent weight loss improves blood pressure, glucose control, and lipid levels. A fifteen percent reduction produces even greater metabolic benefit.

Cardiovascular Benefits Beyond Weight Loss

One of the most important findings comes from cardiovascular outcome trials.

The SUSTAIN 6 trial demonstrated that semaglutide reduced major adverse cardiovascular events in patients with type 2 diabetes. More recently, the SELECT trial showed cardiovascular benefit even in individuals with obesity but without diabetes.

This suggests that GLP 1 receptor agonists may reduce heart attack and stroke risk beyond their effect on weight alone.

Common Side Effects Observed In Clinical Trials

Across randomized trials, gastrointestinal symptoms were the most frequently reported side effects. Nausea, vomiting, and diarrhea were common during early dose escalation phases.

Most adverse effects were mild to moderate and often improved over time. Gradual dose titration reduced intolerance in many participants.

Discontinuation rates due to side effects were present but not excessive compared to other long term metabolic therapies.

Pancreatitis And Cancer Concerns

Safety concerns have included possible pancreatitis and cancer risk. Large meta analyses have not demonstrated a consistent increase in pancreatic cancer risk in humans.

Rodent studies showed thyroid C cell tumors at very high doses, leading to precautionary labeling. However, long term human data have not shown a confirmed increase in medullary thyroid carcinoma. Surveillance continues.

Gallbladder events were slightly increased in some trials, likely related to rapid weight loss rather than a direct toxic effect of the medication.

What Happens After Stopping Treatment

Extension studies provide an important insight. Participants who discontinued semaglutide regained a portion of lost weight over time.

This finding supports the understanding of obesity as a chronic metabolic condition. Like hypertension or diabetes, long term management may require sustained intervention rather than short term therapy.

Affordability And Access Considerations

While clinical efficacy is strong, cost and access remain major barriers in many countries. GLP 1 receptor agonists are significantly more expensive than traditional oral weight management medications.

Healthcare systems must balance clinical benefit with sustainability and equitable access.

What The Evidence Means

The strongest available evidence comes from large randomized controlled trials involving thousands of participants across multiple countries.

These studies consistently demonstrate substantial weight loss and cardiovascular benefit with generally acceptable safety profiles under medical supervision.

However, long term pharmacovigilance, cost effectiveness analysis, and equitable implementation remain important next steps.

GLP 1 medications represent a major development in obesity treatment, but they are not a standalone solution. Lifestyle modification remains foundational, and long term management strategies must be individualized.

References

Wilding JPH et al. Once Weekly Semaglutide In Adults With Overweight Or Obesity. New England Journal of Medicine. 2021.
Marso SP et al. Semaglutide And Cardiovascular Outcomes In Patients With Type 2 Diabetes. New England Journal of Medicine. 2016.
SELECT Trial Investigators. Semaglutide And Cardiovascular Outcomes In Overweight Or Obese Patients. New England Journal of Medicine. 2023.
Bethel MA et al. Assessing The Safety Of Incretin Based Therapies. The Lancet Diabetes And Endocrinology.